Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

被引：6
作者：
Yap, Timothy A. [1 ,2 ]
Popat, Sanjay [1 ,3 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Inst Canc Res, London, England
[3] Imperial Coll London, Natl Heart & Lung Inst, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
ACQUIRED-RESISTANCE; AMPLIFICATION; INHIBITORS; MUTATIONS; CARCINOMA;
D O I：
10.1016/j.jtho.2016.10.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [41] Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
    Wolf, Juergen
    Seto, Takashi
    Han, Ji-Youn
    Reguart, Noemi
    Garon, Edward B.
    Groen, Harry J. M.
    Tan, Daniel S. W.
    Hida, Toyoaki
    de Jonge, Maja
    Orlov, Sergey V.
    Smit, Egbert F.
    Souquet, Pierre-Jean
    Vansteenkiste, Johan
    Hochmair, Maximilian
    Felip, Enriqueta
    Nishio, Makoto
    Thomas, Michael
    Ohashi, Kadoaki
    Toyozawa, Ryo
    Overbeck, Tobias R.
    de Marinis, Filippo
    Kim, Tae-Min
    Laack, Eckart
    Robeva, Anna
    Le Mouhaer, Sylvie
    Waldron-Lynch, Maeve
    Sankaran, Banu
    Balbin, O. Alejandro
    Cui, Xiaoming
    Giovannini, Monica
    Akimov, Mikhail
    Heist, Rebecca S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10) : 944 - 957
  • [42] Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
    Tan, Aaron C.
    Loh, Tracy J.
    Kwang, Xue Lin
    San Tan, Gek
    Lim, Kiat Hon
    Tan, Daniel S. W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 11 - 20
  • [43] Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
    Wu, Yi-Long
    Smit, Egbert F.
    Bauer, Todd M.
    CANCER TREATMENT REVIEWS, 2021, 95
  • [44] The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation
    Rocco, Danilo
    Della Gravara, Luigi
    Palazzolo, Giovanni
    Gridelli, Cesare
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (21) : 3043 - 3056
  • [45] Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
    Pruis, M. A.
    Geurts-Giele, W. R. R.
    von der Thusen, J. H.
    Meijssen, I. C.
    Dinjens, W. N. M.
    Aerts, J. G. J., V
    Dingemans, A. M. C.
    Lolkema, M. P.
    Paats, M. S.
    Dubbink, H. J.
    LUNG CANCER, 2020, 140 : 46 - 54
  • [46] MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance
    Guo, Robin
    Offin, Michael
    Brannon, A. Rose
    Chang, Jason
    Chow, Andrew
    Delasos, Lukas
    Girshman, Jeffrey
    Wilkins, Olivia
    McCarthy, Caroline G.
    Makhnin, Alex
    Falcon, Christina
    Scott, Kerry
    Tian, Yuan
    Cecchi, Fabiola
    Hembrough, Todd
    Alex, Deepu
    Shen, Ronglai
    Benayed, Ryma
    Li, Bob T.
    Rudin, Charles M.
    Kris, Mark G.
    Arcila, Maria E.
    Rekhtman, Natasha
    Paik, Paul
    Zehir, Ahmet
    Drilon, Alexander
    CLINICAL CANCER RESEARCH, 2021, 27 (03) : 799 - 806
  • [47] Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report
    Ikeo, Satoshi
    Yasuda, Naoaki
    Sakai, Yuki
    Hayashi, Yasuyuki
    Sokai, Akihiko
    Iwata, Toshiyuki
    Nishimura, Takashi
    THORACIC CANCER, 2023, 14 (10) : 958 - 960
  • [48] Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
    Drilon, Alexander
    Clark, Jeffrey W.
    Weiss, Jared
    Ou, Sai-Hong Ignatius
    Camidge, D. Ross
    Solomon, Benjamin J.
    Otterson, Gregory A.
    Villaruz, Liza C.
    Riely, Gregory J.
    Heist, Rebecca S.
    Awad, Mark M.
    Shapiro, Geoffrey I.
    Satouchi, Miyako
    Hida, Toyoaki
    Hayashi, Hidetoshi
    Murphy, Danielle A.
    Wang, Sherry C.
    Li, Sherry
    Usari, Tiziana
    Wilner, Keith D.
    Paik, Paul K.
    NATURE MEDICINE, 2020, 26 (01) : 47 - +
  • [49] MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping
    Tsai, Jonathan M.
    Hata, Aaron N.
    Lennerz, Jochen K.
    ONCOLOGIST, 2021, 26 (12) : E2297 - E2301
  • [50] Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
    Drilon, Alexander
    Cappuzzo, Federico
    Ignatius, Sai-Hong
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : 15 - 26
12345